Additionally, RET-mediated endocrine resistance in ER+ breast cancer cells may be attributed to the finding that RET is an ER target gene and that RET and ERα stimulate unique pathways in luminal breast cancers, thus providing biological rationale for dual targeting of these two receptors to combat hormone resistance in luminal breast cancers (153–157). This evidence concerns the gene ESR1 and breast carcinoma.